DK2549276T3 - Reversibel, kovalent binding af funktionelle molekyler - Google Patents
Reversibel, kovalent binding af funktionelle molekyler Download PDFInfo
- Publication number
- DK2549276T3 DK2549276T3 DK12189317.6T DK12189317T DK2549276T3 DK 2549276 T3 DK2549276 T3 DK 2549276T3 DK 12189317 T DK12189317 T DK 12189317T DK 2549276 T3 DK2549276 T3 DK 2549276T3
- Authority
- DK
- Denmark
- Prior art keywords
- group
- formula
- compound
- groups
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- General Physics & Mathematics (AREA)
Claims (15)
1. Anvendelse af en forbindelse med formlen (la) som et reagent for binding af en forbindelse med formlen RrH, der omfatter en første funktionel del med formlen F-ι, til en anden funktionel del med formlen F2
hvor: - X og X'hver repræsenterer oxygen; - Y er en elektrofil fraspaltelig gruppe; - R3 og R3' sammen danner en gruppe med formlen -N(R33·), hvor R33' repræsenterer et hydrogenatom eller en gruppe med formlen Y, Nu, -L(Z)n eller IG; - R2 repræsenterer et hydrogenatom eller en gruppe med formlen Y, Y, Nu, -L(Z)n eller IG; - hver gruppe med formlen Y er ens eller forskellig og repræsenterer en elektrofil fraspaltelig gruppe; - hver gruppe med formlen Nu er ens eller forskellig og repræsenterer en nukleofil udvalgt fra -OH, -SH, -NH2 og -NH(Ci-6-alkyl); - hver gruppe med formlen L er ens eller forskellig og repræsenterer en linker-gruppe; - hver gruppe med formlen Z er ens eller forskellig og repræsenterer en reaktiv gruppe bundet til en gruppe med formlen L, der er i stand til at blive omsat med en forbindelse, der indeholder en anden funktionel del som defineret i krav 1, således at den anden funktionelle del bindes til gruppen med formlen L; - n er 1,2 eller 3; og - hver gruppe med formlen IG er ens eller forskellig og repræsenterer en del der er en Ci-20-alkylgruppe, en C2.2o-alkenylgruppe eller en C2.20-alkynyl-gruppe, der er ikke-substitueret eller substitueret med én eller flere substituen-ter udvalgt fra halogenatomer og sulfonsyregrupper, og hvori (a) 0, 1 eller 2 carbonatomer er erstattet af grupper udvalgt fra C6-io-arylen, 5- til 10-leddet he-teroarylen, C3-7-carboclyclen og 5- til 10-leddet heterocyclylengrupper, og (b) 0, 1 eller 2 -CH2-grupper er erstattet af grupper udvalgt fra -O-, -S-, -S-S-, C(O)-og -N(Ci-6-alkyl)- grupper, hvor: (i) arylen-, heteroarylen-, carbocyclylen- og heterocyclylen-grupperne er ikke-substituerede eller substituerede med én eller flere substituenter, der er udvalgt fra halogenstomer og Ci-6-alkyl, Ci-6-alkoxy, Ci-6-alkylthiol, -N(Ci-6-al-kyl)(Ci-6-alkyl), nitro- og sulfonsyregrupper; og (ii) 0, 1 eller 2 carbonatomer i carbocyclylen- og heterocyclylengrupperne er erstattet af C(0)-grupper; og - enten: - den første funktionelle del eller den anden funktionelle del er et protein, der er et antistof eller antistoffragment, som kan binde til et specifikt antigen via en epitop på antigenet, og den anden af den første funktionelle del og den anden funktionelle del er et lægemiddel, eller - den første funktionelle del eller den anden funktionelle del er en polymerdel, der er udvalgt fra peptider, proteiner, polysaccharider, polyethere, poly-aminosyrer, polyvinylalkoholer, polyvinylpyrrolidoner, poly(meth)acrylsyre og derivater deraf, polyurethaner og polyphosphazener, og den anden af den første funktionelle del og den anden funktionelle del er et lægemiddel; hvor gruppen R-ι bindes til forbindelsen med formlen (la) via nukleofilt angreb af den første SH-gruppe i forbindelsen med formlen RrH ved 2-posi-tionen af forbindelsen med formlen (la), således at gruppen Y ved 2-positionen erstattes af gruppen Ri.
2. Anvendelse ifølge krav 1, hvor: (A) : Y er et halogenatom eller et triflat, tosylat, mesylat, N-hydroxysuccinimidyl, Nhydroxysulfosuccinimidyl, C-i-6-allcylthiol, 5- til 10-leddet heterocyclylthiol, C6-io-arylthiol, C3-7-carbocyclylthiol, -0C(0)CH3, -0C(0)CF3, phenyloxy, en -NRX-RyRz+- eller -PRxRyRz+-gruppe, hvori Rx, Ryog Rz er ens eller forskellige og er udvalgt fra hydrogenatomer og Ci-6-alkyl og phenylgrupper; og/eller (B) : L repræsenterer en del, der er en Ci-2o-alkylengruppe, en C2.20-alkenylen-gruppe eller en C2.2o-alkynylengruppe, der er ikke-substitueret eller substitueret med én eller flere substituenter, der er udvalgt fra halogenstomer og sulfonsy-regrupper, og hvori (a) 0, 1 eller 2 carbonatomer er erstattet af grupper udvalgt fra C6-io-arylen, 5- til 10-leddet heteroarylen, C3-7-carbocyclylen og 5- til 10-led-dede heterocyclylengrupper, og (b) 0,1 eller 2 -CH2-grupper er erstattet af grupper udvalgt fra -0-, -S-, -S-S-, C(O)- og -N-(i-e-alkyl)-grupper, hvor: (i) arylen-, heteroarylen-, carbocyclylen- og heterocyclylen-grupperne er ikke-substituerede eller substituerede med én eller flere substituenter, der er udvalgt fra halogenatomer og Ci-6-alkyl, Ci-6-alkoxy, Ci-6-alkylthiol, -N(Ci-6-al-kyl)(Ci-6-alkyl), nitro- og sulfonsyregrupper; og (ii) 0, 1 eller 2 carbonatomer i carbocyclylen- og heterocyclylengrupperne er erstattet af C(O)- grupper; og/eller (C): Z repræsenterer: (a) en gruppe med formlen -LG, -C(0)-LG, -C(S)-LG eller -C(NH)-LG, hvor LG er en elektrofil fraspaltelig gruppe; (b) en nukleofil Nu' udvalgt fra -OH, -SH, -NH2, -NH(Ci-6-alkyl) og -C(0)NH-NH2 grupper; (c) en cyklisk del Cyc, der er i stand til at foranledige en ringåbnende elektrofil reaktion med en nukleofil; (d) en gruppe med formlen -S(02)(Hal), hvor Hal er et halogenatom; (e) en gruppe med formlen -N=C=0 eller -N=C=S; (f) en gruppe med formlen -S-S(IG’), hvor IG' repræsenterer en gruppe med formlen IG som defineret i krav 2; (g) en gruppe AH, der er en C6-io-arylgruppe, der er substitueret med ét eller flere halogenatomer; (h) en fotoreaktiv gruppe, der kan aktiveres ved eksponering for ultraviolet lys; (i) en gruppe med formlen -C(0)H eller -C(0)(Ci-6-alkyl); (j) en maleimido-gruppe; (k) en gruppe med formlen -C(0)CHCH2; (l) en gruppe med formlen -C(0)C(N2)H eller -PhN2+, hvor Ph repræsenterer en phenylgruppe; eller (m) en epoxidgruppe; og/eller (D) : IG repræsenterer en del der er en ikke-substitueret Ci-6-alkylgruppe, C2.6-alkenylgruppe eller C2-6-alkynylgruppe, hvori (a) 0 eller 1 carbonatom erstattes af en gruppe udvalgt fra phenylen, 5- til 6-leddet heteroarylen, C5-6-carbocycly-len og 5- til 6-leddet heterocyclylengrupper, hvor phenylen-, heteroarylen-, car-bocyclylen- og heterocyclylen-grupperne er ikke-substituerede eller substituerede med én eller to substituenter, der er udvalgt fra halogenstomer og Ci-4-alkyl og Ci-4-alkoxygrupper, og (b) 0, 1 eller 2 -CH2- grupper er erstattet af grupper udvalgt fra -O-, -S- og C(O)- grupper; og/eller (E) : n er 1.
3. Anvendelse ifølge krav 1 eller 2, hvor forbindelsen med formlen (la) er en forbindelse med formlen (Ib)
(II) hvor: - X og X' hver repræsenterer et oxygenatom; - R33’ repræsenterer et hydrogenatom eller en Ci-6-alkylgruppe; - Y repræsenterer et halogenatom; og - R2 repræsenterer et hydrogen- eller halogenatom eller en Ci-6-alkyl-gruppe.
4. Anvendelse ifølge et hvilket som helst af de foregående krav, hvor: - Ri er en gruppe med formlen-Fi; - Fi er et peptid eller protein omfattende mindst en første cysteinrest; og - gruppen Ri bindes til forbindelsen med formlen (la) via nukleofilt angreb af thiolgruppen i den første cysteinrest ved 2-positionen af forbindelsen med formlen (la), således at gruppen Y erstattes af thiolgruppen i den første cysteinrest i gruppen R-i; og hvor eventuelt: - R2 er en gruppe med formlen Y; - R-ι endvidere omfatter mindst en anden cysteinrest; og - gruppen R-ι endvidere fastgøres til forbindelsen med formlen (la) via nukleofilt angreb af thiolgruppen i den anden cysteinrest ved 3-positionen af delen med formlen (la), således at gruppen R2 erstattes af thiolgruppen i den anden cysteinrest i gruppen R-i.
5. Fremgangsmåde til fremstilling af et konjugat, hvilken fremgangsmåde omfatter (i) omsætning af en forbindelse med formlen (la) med en forbindelse med formlen Ri-H, hvorved der frembringes en forbindelse med formlen (II)
(ii) efterfølgende binding af en del af formlen F2 til forbindelsen med formlen (II); hvor trin (i) involverer binding af gruppen R-ι via nukleofilt angreb af den første SFI-gruppe i forbindelsen med formlen R-i-H ved 2-positionen af forbindelsen med formlen (la), således at gruppen Y ved 2-positionen erstattes af gruppen Ri, og hvor X, X', Y, R-ι, R2, R3, R3, og F2 alle er som defineret i et hvilken som helst af kravene 1 til 4.
6. Fremgangsmåde ifølge krav 5, hvor: (A) : fremgangsmåden omfatter binding af F2 til forbindelsen med formlen (II) via en elektrofil additionsreaktion af F2 over carbon-carbon-dobbeltbindingen mellem 2-positionen og 3-positionen af formlen (II); eller (B) : R33' repræsenterer et hydrogenatom eller en gruppe med formlen Y, Nu eller -L(Z)n og fremgangsmåden omfatter binding af F2 til forbindelsen med formlen (II) via en reaktion mellem F2 og (i) nitrogenatomet af delen med formlen -N-(R33) eller (ii) gruppen med formlen Y, Nu eller -L(Z)n; eller (C) : R2 repræsenterer en gruppe med formlen Y, Nu eller -L(Z)n og fremgangsmåden omfatter binding af F2 til forbindelsen med formlen (II) via en reaktion mellem F2 og gruppen med formlen Y, Nu eller -L(Z)n.
7. Fremgangsmåde til fremstilling af et konjugat, hvilken fremgangsmåde omfatter omsætning af en forbindelse med formlen RrH med en forbindelse med formlen (Ila)
hvor: - R3a og R3a’ sammen danner en gruppe med formlen -N(R33a), hvor R33a’ repræsenterer en gruppe med formlen R33’ eller en gruppe med formlen F2 eller -L(F2)m(Z)n.m; - R2a repræsenterer en gruppe med formlen R2 eller en gruppe med formlen F2 eller --L(F2)m(Z)n-m; - m er et heltal med en værdi på fra nul til n; - forbindelsen med formlen (Ila) omfatter mindst én gruppe med formlen F2; - F2 er som defineret i krav 1; - X, X', R3, R3', R33', R2j L, Z og n alle er som defineret i et hvilket som helst af kravene 1 til 3 - Ri er som defineret i krav 1 eller 4 og - fremgangsmåden involverer binding af gruppen Ri via nukleofilt angreb af den første SH-gruppe i forbindelsen med formlen RrH ved 2-positionen af forbindelsen med formlen (Ila), således at gruppen Y ved 2-positionen erstattes af gruppen Ri.
8. Fremgangsmåde, der omfatter (i) tilvejebringelse af en forbindelse med formlen (III) eller (Illa); og (ii) spaltning af bindingen mellem gruppen Ri og carbonatomet ved 2-positionen af forbindelsen med formlen (III) eller (Illa)
(life) hvor: - R3a og R3a’ sammen danner en gruppe med formlen -N(R33), hvor R33a’ repræsenterer en gruppe med formlen R33, eller en gruppe med formlen F2 eller -L(F2)m(Z)n-m; - R2a repræsenterer en gruppe med formlen R2 eller en gruppe med formlen F2 eller —L(F2)m(Z)n.m, m er et heltal med en værdi på fra nul til n; - Ri er som defineret i krav 1 eller 4; - F2 er som defineret i krav 1; - X, X', R3, R3·, R33', R2, L, Z og n alle er som defineret i et hvilket som helst af kravene 1 til 3; og hvor, når fremgangsmåden involverer forbindelsen med formlen (Ilia): - Ri i forbindelsen med formlen (Illa) omfatter mindst en første thiolgrup-pe og en anden thiolgruppe, hvilken første thiolgruppe er bundet til 2-positionen i forbindelsen med formlen (I I la), og hvilken anden thiolgruppe er bundet til 3-positionen i forbindelsen med formlen (Illa); og - trin (ii) endvidere involverer spaltning af bindingen mellem gruppen Ri og carbonatomet ved 3-positionen af delen med formlen (Illa).
9. Forbindelse, hvilken forbindelse er: (A) en forbindelse med formlen (Ila) som defineret i krav 7; eller (B) en forbindelse med formlen (III) som defineret i krav 8, hvilken forbindelse omfatter mindst én gruppe med formlen F2, og hvori R2a ikke er et hydrogenatom.
10. Forbindelse med formlen (I I la) som defineret i krav 8.
11. Forbindelse ifølge krav 10, hvilken forbindelse omfatter mindst én gruppe med formlen F2.
12. Forbindelse ifølge krav 10 eller 11, hvor er et peptid eller protein, der mindst omfatter to cysteinrester, hvilke cysteinrester fortrinsvis danner en indre disulfidbro i peptidet eller proteinet, når peptidet eller proteinet ikke er bundet i forbindelsen med formlen (Illa).
13. Forbindelse med formlen (IVa) eller (IVb)
hvor - Ri er som defineret i krav 1 eller 4; - X, X', R2a, R3a og R3a’ er som defineret i krav 8; - R4 er et halogenatom, hydroxyl, Ci-6-alkoxy, thiol, Ci-6-alkylthio eller C1-e-alkylcarbonyloxygruppe, eller en gruppe med formlen F2; - mindst én af grupperne R2a og R4 omfatter en gruppe med formlen F2; og - F2 er som defineret i krav 1.
14. Forbindelse som defineret i (B) af krav 9, krav 11 eller krav 13 til anvendelse i en fremgangsmåde til behandling af menneske- eller dyrekroppen ved kirurgi eller terapi eller en diagnostisk metode, der praktiseres på menneske- eller dyrekroppen.
15. Fremgangsmåde som defineret i et hvilket som helst af kravene 5 til 7, hvor konjugatet omfatter en maleimidring og fremgangsmåden endvidere omfatter ringåbning af maleimidringen.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0913967A GB0913967D0 (en) | 2009-08-10 | 2009-08-10 | Functionalisation of solid substrates |
GB0913965A GB0913965D0 (en) | 2009-08-10 | 2009-08-10 | Reversible covalent linkage of functional moieties |
GB0914321A GB0914321D0 (en) | 2009-08-14 | 2009-08-14 | Thiol protecting group |
EP10742867A EP2464972A1 (en) | 2009-08-10 | 2010-08-09 | Reversible covalent linkage of functional molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2549276T3 true DK2549276T3 (da) | 2015-06-08 |
Family
ID=42668730
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15150363.8T DK2889624T3 (da) | 2009-08-10 | 2010-08-09 | Reversibel kovalent binding af funktionelle molekyler |
DK12189317.6T DK2549276T3 (da) | 2009-08-10 | 2010-08-09 | Reversibel, kovalent binding af funktionelle molekyler |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15150363.8T DK2889624T3 (da) | 2009-08-10 | 2010-08-09 | Reversibel kovalent binding af funktionelle molekyler |
Country Status (11)
Country | Link |
---|---|
US (6) | US9295729B2 (da) |
EP (5) | EP2464972A1 (da) |
JP (3) | JP2013501766A (da) |
CN (1) | CN102597773B (da) |
AU (2) | AU2010283632B2 (da) |
BR (1) | BR112012003089A2 (da) |
CA (3) | CA2770617C (da) |
DK (2) | DK2889624T3 (da) |
ES (2) | ES2537623T3 (da) |
IL (2) | IL218010A (da) |
WO (3) | WO2011018612A2 (da) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3243835B1 (en) | 2009-02-11 | 2024-04-10 | Albumedix Ltd | Albumin variants and conjugates |
DK2889624T3 (da) | 2009-08-10 | 2018-12-10 | Ucl Business Plc | Reversibel kovalent binding af funktionelle molekyler |
GB2488077A (en) | 2009-10-30 | 2012-08-15 | Novozymes Biopharma Dk As | Albumin variants |
JP5969458B2 (ja) | 2010-04-09 | 2016-08-17 | アルブミディクス アクティーゼルスカブ | アルブミン誘導体及び変異体 |
US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
IN2014CN04961A (da) * | 2011-12-05 | 2015-09-18 | Igenica Biotherapeutics Inc | |
WO2013121175A1 (en) | 2012-02-16 | 2013-08-22 | Ucl Business Plc | Lysosome-cleavable linker |
CA2866699A1 (en) * | 2012-03-09 | 2013-09-12 | Ucl Business Plc | Chemical modification of antibodies |
MX2014010278A (es) | 2012-03-16 | 2015-03-05 | Novozymes Biopharma Dk As | Variantes de albumina. |
CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
AU2013350802B2 (en) | 2012-11-30 | 2016-07-14 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
MX2015011348A (es) | 2013-03-15 | 2016-01-15 | Regeneron Pharma | Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos. |
WO2014197871A2 (en) * | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates, compositions and methods of use |
US10781259B2 (en) | 2013-06-06 | 2020-09-22 | Magenta Therapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
CN105530942B (zh) | 2013-08-26 | 2019-10-11 | 瑞泽恩制药公司 | 一种包含大环内酯类非对映体的药物组合物、其制备方法和用途 |
KR20160088429A (ko) | 2013-11-26 | 2016-07-25 | 노파르티스 아게 | 케톤-변형된 폴리펩티드에 대한 옥심 접합을 위한 방법 |
EP3126388B1 (en) | 2014-03-11 | 2019-05-08 | Regeneron Pharmaceuticals, Inc. | Anti-egfrviii antibodies and uses thereof |
WO2015179734A1 (en) | 2014-05-23 | 2015-11-26 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
CN105294832B (zh) * | 2014-08-11 | 2020-11-06 | 浙江海洋学院 | 一种缢蛏活性三肽及其制备方法和应用 |
EP3218009B1 (en) | 2014-10-14 | 2021-04-07 | Polytherics Limited | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg |
US10342441B2 (en) | 2015-02-27 | 2019-07-09 | Qualcomm Incorporated | Estimating heart rate by tracking optical signal frequency components |
EP3273998B1 (en) | 2015-03-27 | 2019-09-04 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
CN104910312B (zh) * | 2015-05-28 | 2019-03-15 | 江苏省原子医学研究所 | 一种提高染料荧光强度的线性聚合物及其制备方法和应用 |
EP3319994B1 (en) | 2015-07-06 | 2024-02-07 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
AU2016308504A1 (en) | 2015-08-20 | 2018-01-18 | Albumedix Ltd. | Albumin variants and conjugates |
WO2017089607A1 (en) | 2015-11-27 | 2017-06-01 | Heidelberg Pharma Gmbh | Derivatives of gamma-amanitin |
AU2016366521A1 (en) | 2015-12-11 | 2018-06-21 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to EGFR and/or ErbB3 blockade |
CN114478801A (zh) | 2016-01-25 | 2022-05-13 | 里珍纳龙药品有限公司 | 美登素类化合物衍生物、其偶联物和使用方法 |
EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
US20190328900A1 (en) | 2016-07-01 | 2019-10-31 | Glaxosmithkline Intellectual Property Development Limited | Antibody-drug conjugates and therapeutic methods using the same |
CA3037732A1 (en) | 2016-09-23 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
MD3515487T2 (ro) | 2016-09-23 | 2023-11-30 | Regeneron Pharma | Anticorpi bispecifici anti-MUC16-CD3 și conjugate anticorp anti-MUC16-medicament |
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
JP7330101B2 (ja) | 2016-11-08 | 2023-08-21 | レゲネロン ファーマシューティカルス,インコーポレーテッド | ステロイド及びそのタンパク質コンジュゲート |
TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法 |
US10864279B2 (en) | 2016-12-16 | 2020-12-15 | Industrial Technology Research Institute | Linker-drug and antibody-drug conjugate (ADC) employing the same |
US11491231B2 (en) * | 2017-03-31 | 2022-11-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Peptide-oligonucleotide chimeras (POCs) as programmable biomolecular constructs for the assembly of morphologically-tunable soft materials |
CN110944718A (zh) | 2017-05-18 | 2020-03-31 | 里珍纳龙药品有限公司 | 环糊精蛋白质药物偶联物 |
JP7220199B2 (ja) | 2017-08-07 | 2023-02-09 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | アマニチンの新規な合成方法 |
CA3066867A1 (en) | 2017-08-07 | 2019-02-14 | Heidelberg Pharma Research Gmbh | Novel method for synthesizing amanitins |
DK3684416T3 (da) | 2017-09-22 | 2023-05-15 | Heidelberg Pharma Res Gmbh | Psma-målrettede amanitinkonjugater |
CA3086926A1 (en) | 2018-01-08 | 2019-07-11 | Regeneron Pharmaceuticals, Inc. | Steroids and antibody-conjugates thereof |
IL277572B2 (en) | 2018-03-28 | 2024-05-01 | Ascendis Pharma Oncology Div A/S | IL-2 conjugates |
WO2019185706A1 (en) | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Conjugates |
EP3788075A1 (en) | 2018-04-30 | 2021-03-10 | Regeneron Pharmaceuticals, Inc. | Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof |
BR112020022400A2 (pt) | 2018-05-09 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | anticorpos anti-msr1 e métodos de uso dos mesmos |
JP7477462B2 (ja) | 2018-05-17 | 2024-05-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗cd63抗体、コンジュゲート、及び、それらの使用 |
GB2575793A (en) * | 2018-07-20 | 2020-01-29 | Montanuniv Leoben | Resin composition suitable for printing and printing methods |
CN109293683A (zh) * | 2018-09-05 | 2019-02-01 | 河南师范大学 | 一种还原响应型喜树碱二聚体及基于该喜树碱二聚体的还原敏感的药物传递系统 |
JP2022512057A (ja) * | 2018-12-17 | 2022-02-02 | 栄昌生物制薬(烟台)股▲分▼有限公司 | 抗体薬物複合体のためのリンカーおよびその使用 |
KR20210107752A (ko) | 2018-12-21 | 2021-09-01 | 리제너론 파마슈티칼스 인코포레이티드 | 리파마이신 유사체 및 이의 항체-약물 접합체 |
WO2020172475A1 (en) | 2019-02-21 | 2020-08-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met |
CN114340684A (zh) | 2019-09-16 | 2022-04-12 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
CA3166619A1 (en) | 2020-02-28 | 2021-09-02 | Julian Andreev | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
WO2021211984A1 (en) | 2020-04-16 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | Diels-alder conjugation methods |
EP4161956A1 (en) | 2020-06-03 | 2023-04-12 | Ascendis Pharma Oncology Division A/S | Il-2 sequences and uses thereof |
EP4178625A1 (en) | 2020-07-13 | 2023-05-17 | Regeneron Pharmaceuticals, Inc. | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
MX2023002974A (es) | 2020-09-14 | 2023-05-25 | Regeneron Pharma | Conjugados de anticuerpo-farmaco que comprenden peptidomimeticos glp1 y usos de los mismos. |
CA3190569A1 (en) | 2020-10-22 | 2022-04-28 | Christopher Daly | Anti-fgfr2 antibodies and methods of use thereof |
CN114031719B (zh) * | 2021-11-26 | 2023-11-07 | 珠海宏昌电子材料有限公司 | 双马来酰亚胺-三嗪树脂及其制备方法和应用 |
US20230287138A1 (en) | 2022-01-12 | 2023-09-14 | Regneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
CN114377723B (zh) * | 2022-01-22 | 2022-12-13 | 海南大学 | 一种二氧化钛及其可见光催化产氢 |
WO2023173132A1 (en) | 2022-03-11 | 2023-09-14 | Regeneron Pharmaceuticals, Inc. | Anti-glp1r antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
WO2024020164A2 (en) | 2022-07-21 | 2024-01-25 | Firefly Bio, Inc. | Glucocorticoid receptor agonists and conjugates thereof |
WO2024081151A1 (en) * | 2022-10-11 | 2024-04-18 | Ohio State Innovation Foundation | Detection of an amphiphile using visual inspection of a ligand-modified substrate |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA667583A (en) * | 1963-07-30 | Druey Jean | Tetrahydro-dioxopyridazines and process for their preparation | |
US2861093A (en) * | 1956-09-24 | 1958-11-18 | Eastman Kodak Co | Reaction products of dialkyl phosphorothiolothionates and mucohalic acids |
BE725964A (da) * | 1967-12-23 | 1969-05-29 | ||
DE2032709A1 (en) * | 1970-07-02 | 1972-01-20 | Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen | 2-halo-3-mercapto-maleicaldehydeacids as photo-hardeners - from mucohaloacids and mercaptans with bases in inert solvents |
JPS5440556B2 (da) | 1973-03-13 | 1979-12-04 | ||
GB1544686A (en) * | 1977-07-12 | 1979-04-25 | Ici Ltd | Disperse anthraquinone dyestuffs |
DE3513715A1 (de) | 1985-04-17 | 1986-10-23 | Bayer Ag, 5090 Leverkusen | Polycarbonate mit dichlormaleinimid-endgruppen, ihre herstellung und modifizierung |
US4680272A (en) | 1985-10-23 | 1987-07-14 | University Of California | Method for detecting molecules containing amine or thiol groups |
JPS63145282A (ja) | 1986-12-08 | 1988-06-17 | Taiyo Yakuhin Kogyo Kk | ピリダジン誘導体 |
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
PT100941A (pt) * | 1991-10-11 | 1993-10-29 | Ciba Geigy Ag | Herbicidas a base de eteres ou tioeteres pirimidinilicos ou triazinilicos, e processo para a sua preparacao |
US5414074A (en) | 1992-09-25 | 1995-05-09 | University Of Michigan | Synthesis of C-glycosylated compounds with the use of a mild, iodine-catalyzed reaction |
DE4310141A1 (de) | 1993-03-29 | 1994-10-06 | Boehringer Mannheim Gmbh | Homobidentale trifunktionelle Linker |
GB9801210D0 (en) | 1998-01-21 | 1998-03-18 | Merck Sharp & Dohme | Therapeutic agents |
DE19843873A1 (de) * | 1998-09-25 | 2000-03-30 | Univ Halle Wittenberg | Verfahren zur Bestimmung von Proteaseaktivitäten auf Zelloberflächen |
US7442764B2 (en) | 1999-06-07 | 2008-10-28 | Mirns Bio Corporation | Reversible modification of amine-containing compounds |
GB2352085A (en) | 1999-07-15 | 2001-01-17 | Univ Bristol | Integrated semiconductor optical devices |
DE10032335A1 (de) | 2000-07-04 | 2002-01-17 | Cognis Deutschland Gmbh | Dimethylbenzol-Derivate |
CA2435608A1 (en) | 2001-02-05 | 2002-08-15 | Graffinity Pharmaceutical Design Gmbh | Low affinity screening method |
KR100879693B1 (ko) | 2001-08-17 | 2009-01-21 | 상꾜 아그로 가부시키가이샤 | 2-시클로프로필-6-메틸페놀 |
US7144743B2 (en) | 2002-09-13 | 2006-12-05 | Pall Corporation | Preparation and use of mixed mode solid substrates for chromatography adsorbents and biochip arrays |
US20090074885A1 (en) | 2003-09-08 | 2009-03-19 | Roche Madison Inc. | Reversible Hydrophobic Modification of Drugs for Improved Delivery to Cells |
CA2555711A1 (en) | 2004-02-22 | 2005-09-09 | Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services | Maleiimide anti-tumor phosphatase inhibitors |
WO2005111087A1 (ja) | 2004-05-13 | 2005-11-24 | The Yokohama Rubber Co., Ltd. | マレイミド末端ゴムおよびそれを用いた硬化性組成物 |
CN103893778A (zh) * | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
US20070248950A1 (en) | 2006-04-19 | 2007-10-25 | Analytical Biological Services, Inc. | Supported polydiacetylene 3-D arrays for flourescent or phosphorescent detection |
GB0716783D0 (en) | 2007-08-29 | 2007-10-10 | Ucl Business Plc | New Process |
KR101593158B1 (ko) | 2008-08-07 | 2016-02-12 | 입센 파마 에스.에이.에스. | N-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(gip)의 유사체 |
JP2011530506A (ja) * | 2008-08-07 | 2011-12-22 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | グルコース依存性インスリン分泌刺激ポリペプチドの切り詰められたアナログ |
KR20130133104A (ko) * | 2008-08-07 | 2013-12-05 | 입센 파마 에스.에이.에스 | 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체 |
DK2889624T3 (da) | 2009-08-10 | 2018-12-10 | Ucl Business Plc | Reversibel kovalent binding af funktionelle molekyler |
WO2013121175A1 (en) * | 2012-02-16 | 2013-08-22 | Ucl Business Plc | Lysosome-cleavable linker |
-
2010
- 2010-08-09 DK DK15150363.8T patent/DK2889624T3/da active
- 2010-08-09 CA CA2770617A patent/CA2770617C/en not_active Expired - Fee Related
- 2010-08-09 WO PCT/GB2010/001500 patent/WO2011018612A2/en active Application Filing
- 2010-08-09 JP JP2012524274A patent/JP2013501766A/ja not_active Withdrawn
- 2010-08-09 CN CN201080041653.4A patent/CN102597773B/zh not_active Expired - Fee Related
- 2010-08-09 EP EP10742867A patent/EP2464972A1/en not_active Withdrawn
- 2010-08-09 US US13/389,625 patent/US9295729B2/en active Active
- 2010-08-09 JP JP2012524273A patent/JP2013501765A/ja active Pending
- 2010-08-09 ES ES12189317.6T patent/ES2537623T3/es active Active
- 2010-08-09 AU AU2010283632A patent/AU2010283632B2/en not_active Ceased
- 2010-08-09 CA CA2770626A patent/CA2770626A1/en not_active Abandoned
- 2010-08-09 EP EP10744980A patent/EP2464974A1/en not_active Withdrawn
- 2010-08-09 WO PCT/GB2010/001499 patent/WO2011018611A1/en active Application Filing
- 2010-08-09 DK DK12189317.6T patent/DK2549276T3/da active
- 2010-08-09 EP EP10747930.5A patent/EP2464654B1/en not_active Not-in-force
- 2010-08-09 JP JP2012524272A patent/JP5954789B2/ja active Active
- 2010-08-09 BR BR112012003089A patent/BR112012003089A2/pt not_active IP Right Cessation
- 2010-08-09 US US13/389,613 patent/US20120190579A1/en not_active Abandoned
- 2010-08-09 WO PCT/GB2010/001504 patent/WO2011018613A1/en active Application Filing
- 2010-08-09 ES ES15150363T patent/ES2699312T3/es active Active
- 2010-08-09 EP EP15150363.8A patent/EP2889624B1/en active Active
- 2010-08-09 CA CA2770620A patent/CA2770620A1/en not_active Abandoned
- 2010-08-09 EP EP12189317.6A patent/EP2549276B1/en active Active
- 2010-08-10 US US13/389,616 patent/US20120190814A1/en not_active Abandoned
-
2012
- 2012-02-09 IL IL218010A patent/IL218010A/en active IP Right Grant
-
2016
- 2016-02-17 US US15/045,906 patent/US10174094B2/en active Active
- 2016-05-05 IL IL245506A patent/IL245506A/en active IP Right Grant
- 2016-11-24 AU AU2016262736A patent/AU2016262736B2/en not_active Ceased
-
2018
- 2018-11-21 US US16/198,134 patent/US10548982B2/en active Active
-
2019
- 2019-12-16 US US16/714,975 patent/US10933142B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2549276T3 (da) | Reversibel, kovalent binding af funktionelle molekyler | |
TWI792596B (zh) | 新穎脂肪酸及其於共軛至生物分子之用途 | |
AU2017383008B2 (en) | Peptide ligands for binding to MT1-MMP | |
JP5134374B2 (ja) | ポリペプチドと五糖の複合物 | |
CN108136043B (zh) | 蛋白质缀合物 | |
KR20140045312A (ko) | 방사성표지 her2 결합 펩티드 | |
CA3129576A1 (en) | Long-acting glp-2 analogs |